Peginterferon beta-1a dosed every 2 weeks maintained efficacy over 3 years in patients with relapsing-remitting multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2015
This article has no abstract
Epistemonikos ID: c94dff565e3e3a9802a612338c650dc38c3c3cd1
First added on: Apr 30, 2026